SMA Capital’s Arcus Biosciences RCUS Stock Holding History

SMA Capital’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.4K	Buy	338 +80	+31%	+$1.98K	﹤0.01%	109
2026 Q1	$5.57K	Buy	+258	New	+$5.57K	﹤0.01%	88

Other funds holding RCUS

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

SMA Capital's RCUS Position: Q2 2026 in Review

SMA Capital increased its Arcus Biosciences (RCUS) stake by 31% in Q2 2026, buying an estimated $1.98K and bringing the position to 338 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #109.

SMA Capital first reported a position in RCUS in Q1 2026 and has held it in 2 quarters since. 230 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

SMA Capital held 338 shares of Arcus Biosciences worth $10.4K as of Q2 2026.
SMA Capital bought 80 Arcus Biosciences shares in Q2 2026, an estimated $1.98K.
Arcus Biosciences made up ﹤0.01% of SMA Capital's portfolio in Q2 2026, its #109 holding.
SMA Capital first reported a position in Arcus Biosciences in Q1 2026 and has held it in 2 quarters since.
230 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on SMA Capital's 13F filing for Q2 2026, filed 14 Aug 2026.